Evan Feinberg, Genesis Therapeutics CEO

An­dreessen Horowitz-backed start­up lands $200M for AI-based drug dis­cov­ery

Gen­e­sis Ther­a­peu­tics, a start­up us­ing ar­ti­fi­cial in­tel­li­gence to de­sign small mol­e­cule drugs, has raised $200 mil­lion in Se­ries B fi­nanc­ing — one of the largest rounds for an AI-fo­cused biotech this year.

The round is be­ing co-led by An­dreessen Horowitz (a16z) Bio + Health and an anony­mous life sci­ence in­vestor. The Burlingame, CA-based com­pa­ny, which pre­vi­ous­ly struck part­ner­ships with Eli Lil­ly and Genen­tech, will use the mon­ey to fur­ther de­vel­op its gen­er­a­tive and pre­dic­tive AI tech­nolo­gies, ex­pand its pipeline, and move its first com­put­er-gen­er­at­ed drugs in­to clin­i­cal stud­ies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.